JP2021501744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501744A5 JP2021501744A5 JP2020519761A JP2020519761A JP2021501744A5 JP 2021501744 A5 JP2021501744 A5 JP 2021501744A5 JP 2020519761 A JP2020519761 A JP 2020519761A JP 2020519761 A JP2020519761 A JP 2020519761A JP 2021501744 A5 JP2021501744 A5 JP 2021501744A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- sequences
- sequence
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195779.8A EP3470426A1 (en) | 2017-10-10 | 2017-10-10 | Multispecific antibody |
| EP17195779.8 | 2017-10-10 | ||
| EP18150465 | 2018-01-05 | ||
| EP18150465.5 | 2018-01-05 | ||
| EP18167093 | 2018-04-12 | ||
| EP18167093.6 | 2018-04-12 | ||
| EP18180814 | 2018-06-29 | ||
| EP18180814.8 | 2018-06-29 | ||
| PCT/EP2018/077509 WO2019072868A1 (en) | 2017-10-10 | 2018-10-09 | MULTISPECIFIC ANTIBODIES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501744A JP2021501744A (ja) | 2021-01-21 |
| JP2021501744A5 true JP2021501744A5 (enExample) | 2021-11-18 |
| JP7442443B2 JP7442443B2 (ja) | 2024-03-04 |
Family
ID=63799025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519761A Active JP7442443B2 (ja) | 2017-10-10 | 2018-10-09 | 多重特異性抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12202911B2 (enExample) |
| EP (1) | EP3694873A1 (enExample) |
| JP (1) | JP7442443B2 (enExample) |
| KR (1) | KR102907331B1 (enExample) |
| CN (1) | CN111194323B (enExample) |
| AU (1) | AU2018348429B2 (enExample) |
| BR (1) | BR112020006999A2 (enExample) |
| CA (1) | CA3075969A1 (enExample) |
| CL (2) | CL2020000937A1 (enExample) |
| CO (1) | CO2020003882A2 (enExample) |
| IL (1) | IL273576B2 (enExample) |
| MA (1) | MA50352A (enExample) |
| MX (1) | MX2020003562A (enExample) |
| PE (1) | PE20200849A1 (enExample) |
| SG (1) | SG11202002982YA (enExample) |
| WO (1) | WO2019072868A1 (enExample) |
| ZA (1) | ZA202001294B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| CN110709418B (zh) * | 2017-06-05 | 2023-09-26 | 努玛治疗有限公司 | 新型抗hsa抗体 |
| CN111183159B (zh) * | 2017-10-10 | 2024-09-03 | 努玛治疗有限公司 | 靶向cd137的抗体及其使用方法 |
| CA3082297A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| TWI839395B (zh) * | 2018-10-09 | 2024-04-21 | 瑞士商Ｎｕｍａｂ治療公司 | 靶向cd137的抗體及其使用方法 |
| WO2021013142A1 (zh) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |
| JP7634001B2 (ja) | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| JP7675083B2 (ja) * | 2020-01-09 | 2025-05-12 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規４－１ｂｂｌ三量体含有抗原結合分子 |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| MX2022014768A (es) * | 2020-05-29 | 2023-01-11 | Numab Therapeutics AG | Anticuerpo multiespecifico. |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| WO2022136693A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| EP4373848A2 (en) | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
| EP4273162A1 (en) | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| CN119487062A (zh) | 2022-05-06 | 2025-02-18 | 努玛治疗有限公司 | 具有降低的免疫原性的抗体可变结构域和抗体 |
| PE20260551A1 (es) | 2023-05-19 | 2026-03-04 | Numab Therapeutics AG | Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida |
| IL328540A (en) | 2023-12-22 | 2026-07-01 | Numab Therapeutics AG | Antibody binding complexes specific for LILRB2 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20040071705A1 (en) | 2002-06-21 | 2004-04-15 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| JP2006500921A (ja) | 2002-07-30 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヒト４−１ｂｂに対するヒト化抗体 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PL3241842T3 (pl) | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2011006915A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| JP6696982B2 (ja) * | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| MA42971A (fr) * | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| KR20250091329A (ko) | 2015-06-15 | 2025-06-20 | 누맙 세러퓨틱스 아게 | 이종 이량체 다중 특이적 항체 포맷 |
| WO2017102835A1 (en) * | 2015-12-14 | 2017-06-22 | Complix Nv | Binding molecule comprising an alphabody-polypeptide and an antibody |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| CN111183159B (zh) | 2017-10-10 | 2024-09-03 | 努玛治疗有限公司 | 靶向cd137的抗体及其使用方法 |
| IL273578B2 (en) | 2017-10-10 | 2026-03-01 | Numab Therapeutics AG | Antibodies directed against PD-1 and methods of use thereof |
-
2018
- 2018-10-09 US US16/754,604 patent/US12202911B2/en active Active
- 2018-10-09 MX MX2020003562A patent/MX2020003562A/es unknown
- 2018-10-09 MA MA050352A patent/MA50352A/fr unknown
- 2018-10-09 SG SG11202002982YA patent/SG11202002982YA/en unknown
- 2018-10-09 WO PCT/EP2018/077509 patent/WO2019072868A1/en not_active Ceased
- 2018-10-09 JP JP2020519761A patent/JP7442443B2/ja active Active
- 2018-10-09 PE PE2020000430A patent/PE20200849A1/es unknown
- 2018-10-09 IL IL273576A patent/IL273576B2/en unknown
- 2018-10-09 KR KR1020207010048A patent/KR102907331B1/ko active Active
- 2018-10-09 CN CN201880065327.3A patent/CN111194323B/zh active Active
- 2018-10-09 CA CA3075969A patent/CA3075969A1/en active Pending
- 2018-10-09 EP EP18783483.3A patent/EP3694873A1/en active Pending
- 2018-10-09 BR BR112020006999-0A patent/BR112020006999A2/pt unknown
- 2018-10-09 AU AU2018348429A patent/AU2018348429B2/en active Active
-
2020
- 2020-02-28 ZA ZA2020/01294A patent/ZA202001294B/en unknown
- 2020-03-30 CO CONC2020/0003882A patent/CO2020003882A2/es unknown
- 2020-04-07 CL CL2020000937A patent/CL2020000937A1/es unknown
-
2021
- 2021-01-06 CL CL2021000028A patent/CL2021000028A1/es unknown
-
2025
- 2025-01-20 US US19/032,151 patent/US20260201070A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537520A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| JP2022523442A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2015535828A5 (enExample) | ||
| JP2013121353A5 (enExample) | ||
| JP2016135783A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| JP2018021031A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2011173884A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2023545183A5 (enExample) | ||
| JP2014509187A5 (enExample) | ||
| EP2604280A3 (en) | Compositions and methods for inhibiting PDGFRBETA and VEGF-A | |
| JP2023093753A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2023545182A5 (enExample) | ||
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| CA2818635C (en) | Antibodies selective for cells presenting erbb2 at high density | |
| JP2013519364A5 (enExample) | ||
| NZ603529A (en) | Antibodies to human gdf8 | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| JP2017526339A5 (enExample) | ||
| JP2014508511A5 (enExample) |